Clinical Trials Sponsored by FibroGen

Total 64 results

FibroGen

Active, not recruiting

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD (LELANTOS-2)

Duchenne Muscular Dystrophy

United States, Spain, Canada, Australia, China, Italy, Belgium, France, Netherlands, Austria, United Kingdom
FibroGen

Completed

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, New Zealand, India, South Africa, Australia, Bulgaria, Canada
FibroGen

Terminated

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease

United States
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Anemia

China
FibroGen

Terminated

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

Liver Fibrosis Due to Chronic Hepatitis B Infection

Hong Kong, Thailand
FibroGen

Completed

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

Anemia in Chronic Kidney Disease

China
FibroGen

Completed

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

Healthy Adult Subjects
FibroGen

Terminated

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) (LELANTOS-1)

Duchenne Muscular Dystrophy

United States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
FibroGen

Active, not recruiting

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

Pancreatic Cancer Non-resectable

United States, Canada, France, Germany, Spain, Korea, Republic of, Austria, Italy, China, Belgium, Israel, United Kingdom
FibroGen

Completed

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
FibroGen

Completed

A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Chemotherapy Induced Anemia

China
FibroGen

Completed

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Pancreatic Cancer (Unresectable)

United States
FibroGen

Terminated

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

COVID-19

United States
FibroGen

Completed

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

CKD Anemia in Dialysis Participants

China
FibroGen

Completed

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

Anemia

China
FibroGen

Completed

A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer

United States
FibroGen

Terminated

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, China, Australia, Korea, Republic of, Taiwan, Russian Federation, Hong Kong, Argentina, Chile
FibroGen

Terminated

Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, France, United Kingdom, Korea, Republic of, Lebanon, Denmark, China, Italy, Spain, Serbia, Germany, Netherlands, Czechia, Brazil, Poland, Argentina, Colombia, Dominican Republic, Georgia, Hungary, Ireland, Mexico, Peru, Switzerlan... and more
FibroGen

Terminated

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (MISSION)

Duchenne Muscular Dystrophy

United States
FibroGen

Completed

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis (FGCL-3019-049)

Idiopathic Pulmonary Fibrosis

United States
FibroGen

Completed

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

Diabetes Mellitus | Diabetic Nephropathy

United States
FibroGen

Terminated

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis

United States
FibroGen

Completed

Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Diabetes Mellitus

United States
FibroGen

Completed

A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

Renal Anemia

United States
FibroGen
AstraZeneca

Withdrawn

Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Anemia Associated With Chronic Kidney Disease

United States
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (ASPEN)

Anemia Associated With End Stage Renal Disease

United States
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Anemia Associated With End Stage Renal Disease (ESRD)

United States
AstraZeneca
FibroGen

Completed

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Anemia

United States, Spain, Thailand, Vietnam, Turkey, Canada, Korea, Republic of, Brazil, Hungary, India, Peru, Philippines, Taiwan, Germany, Slovakia, Russian Federation, Ukraine, Czechia, Poland, Argentina, Bulgaria, Colombia, Malaysia, ... and more
AstraZeneca
FibroGen

Completed

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

Anemia

United States, Thailand, Vietnam, Canada, Peru, Philippines, Slovakia, Poland, Russian Federation, Ukraine, Czechia, Spain, Hungary, Australia, Bulgaria, India, Mexico, Sweden
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia

Japan
FibroGen
Astellas Pharma Inc

Completed

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

Anemia | Chronic Kidney Disease

United States
Astellas Pharma Inc
FibroGen

Completed

A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment

Hemodialysis Patients With Renal Anemia

Japan
Astellas Pharma Inc
FibroGen

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate

Healthy Subjects

Japan
Astellas Pharma Inc
FibroGen

Completed

A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517

Healthy Subjects

Japan
Microgen

Recruiting

Clinical Study in the Treatment of Patients With Moderate Course of COVID-19

COVID-19

Russian Federation
Astellas Pharma Inc
FibroGen

Completed

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

Chronic Kidney Disease

Japan
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Anemia | Chronic Kidney Disease

United States, Puerto Rico
Astellas Pharma Inc
FibroGen

Completed

Pharmacokinetic Study of ASP1517 With Kremezin®

Healthy Volunteers

Japan
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Anemia | End Stage Renal Disease

United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Completed

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Anemia | End Stage Renal Disease | Chronic Kidney Disease

Puerto Rico, United States
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Microgen LLC

Recruiting

Reducing Pregnancy Risks: The Mastery Lifestyle Intervention (MLI)

Preterm Birth | Mental Health Wellness 1

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine

3

Subscribe